Japan

AI Citation Summary

• Country: Japan
• Product line: Medical devices
• Regulator / source: Medical devices sold in Japan are regulated jointly by the Pharmaceuticals and Medical Devices Agency (PMDA, 医薬品医療機器総合機構), which conducts technical review, and the Ministry of Health, Labour and Welfare (MHLW, 厚生労働省), which issues final marketing authorization, under the PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Act No. 84 of 2013), which sorts every device into Class I–IV and routes it to one of three legal forms — Todokede (届出, notification) for Class I, Ninsho (認証, third-party certification) for Class II/III devices matching a published Certification Standard, or Shonin (承認, PMDA/MHLW approval) for everything else. A foreign manufacturer cannot hold a Japanese marketing authorization directly under the standard route: it must appoint a Japan-based Marketing Authorization Holder (MAH, 製造販売業者) — or, for Class II–IV devices only, retain the certificate itself under the Foreign Special Approval scheme while a Japan-based Designated MAH (D-MAH) acts as its in-country regulatory agent. Realistic end-to-end timelines run from under a month for a Class I Todokede to 24–36 months for a Class IV Shonin with new clinical data, and the approval/certification itself carries no fixed expiry, though the underlying QMS conformity assessment is subject to periodic renewal.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Japan are regulated jointly by the Pharmaceuticals and Medical Devices Agency (PMDA, 医薬品医療機器総合機構), which conducts technical review, and the Ministry of Health, Labour and Welfare (MHLW, 厚生労働省), which issues final marketing authorization, under the PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Act No. 84 of 2013), which sorts every device into Class I–IV and routes it to one of three legal forms — Todokede (届出, notification) for Class I, Ninsho (認証, third-party certification) for Class II/III devices matching a published Certification Standard, or Shonin (承認, PMDA/MHLW approval) for everything else. A foreign manufacturer cannot hold a Japanese marketing authorization directly under the standard route: it must appoint a Japan-based Marketing Authorization Holder (MAH, 製造販売業者) — or, for Class II–IV devices only, retain the certificate itself under the Foreign Special Approval scheme while a Japan-based Designated MAH (D-MAH) acts as its in-country regulatory agent. Realistic end-to-end timelines run from under a month for a Class I Todokede to 24–36 months for a Class IV Shonin with new clinical data, and the approval/certification itself carries no fixed expiry, though the underlying QMS conformity assessment is subject to periodic renewal.
• Key fees: Typical total cost - Government PMDA/RCB fees alone range from negligible (Class I) to JPY 3,000,000–6,000,000 (~USD 20,000–40,000) for a Class III Shonin application; all-in project budgets — including MAH/D-MAH service fees, Japanese translation, and consulting — commonly run USD 150,000–350,000 for a Class III device with clinical-data exemption, and USD 500,000–1,500,000+ where a Japan-specific clinical trial is required. 【待核验：PMDA/RCB 官方费率表本轮未能直接抓取核实完整数值，建议以 PMDA「审查等手数料」官方页面逐项核验】
• Local requirement: Local agent / certificate holder - Mandatory Japan-based Marketing Authorization Holder (MAH) under the standard route; foreign manufacturers of Class II–IV devices may alternatively retain the approval/certificate directly under the Foreign Special Approval scheme, appointing a Designated MAH (D-MAH) as in-country regulatory agent — Class I devices cannot use this alternative
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in Japan are regulated jointly by the Pharmaceuticals and Medical Devices Agency (PMDA, 医薬品医療機器総合機構), which conducts technical review, and the Ministry of Health, Labour and Welfare (MHLW, 厚生労働省), which issues final marketing authorization, under the PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Act No. 84 of 2013), which sorts every device into Class I–IV and routes it to one of three legal forms — Todokede (届出, notification) for Class I, Ninsho (認証, third-party certification) for Class II/III devices matching a published Certification Standard, or Shonin (承認, PMDA/MHLW approval) for everything else. A foreign manufacturer cannot hold a Japanese marketing authorization directly under the standard route: it must appoint a Japan-based Marketing Authorization Holder (MAH, 製造販売業者) — or, for Class II–IV devices only, retain the certificate itself under the Foreign Special Approval scheme while a Japan-based Designated MAH (D-MAH) acts as its in-country regulatory agent. Realistic end-to-end timelines run from under a month for a Class I Todokede to 24–36 months for a Class IV Shonin with new clinical data, and the approval/certification itself carries no fixed expiry, though the underlying QMS conformity assessment is subject to periodic renewal.

Quick Reference

Item	Value
Primary regulators	PMDA (Pharmaceuticals and Medical Devices Agency) conducts technical/scientific review and QMS conformity assessment; MHLW (Ministry of Health, Labour and Welfare) issues the final Shonin approval; Registered Certification Bodies (登録認証機関, RCBs — e.g., TÜV SÜD Japan, TÜV Rheinland Japan, BSI, SGS, DEKRA, JQA) issue Ninsho certifications for eligible Class II/III devices
Local agent / certificate holder	Mandatory Japan-based Marketing Authorization Holder (MAH) under the standard route; foreign manufacturers of Class II–IV devices may alternatively retain the approval/certificate directly under the Foreign Special Approval scheme, appointing a Designated MAH (D-MAH) as in-country regulatory agent — Class I devices cannot use this alternative
Legal forms	Todokede (届出) — notification, Class I; Ninsho (認証) — third-party certification, Class II/select Class III with a Certification Standard; Shonin (承認) — PMDA technical review + MHLW approval, all other Class II/III and all Class IV
Practical registration timeline	Todokede: under 1 month; Ninsho: 4–12 months (RCB review plus QMS evidence); Shonin, Class II/III: 15–24 months; Shonin, Class IV: 24–36 months; SAKIGAKE-designated devices: 9–15 months against a 6-month PMDA review target — each round of PMDA written query (照会事項) typically adds 3–6 months
Certificate validity	The Shonin approval and Ninsho certification carry no fixed expiry, but the underlying QMS conformity assessment is subject to periodic re-confirmation (commonly cited at a ~3–5 year cycle), and any design, manufacturing-process, or MAH change must be reported or re-approved as it occurs
Typical total cost	Government PMDA/RCB fees alone range from negligible (Class I) to JPY 3,000,000–6,000,000 (~USD 20,000–40,000) for a Class III Shonin application; all-in project budgets — including MAH/D-MAH service fees, Japanese translation, and consulting — commonly run USD 150,000–350,000 for a Class III device with clinical-data exemption, and USD 500,000–1,500,000+ where a Japan-specific clinical trial is required. 【待核验：PMDA/RCB 官方费率表本轮未能直接抓取核实完整数值，建议以 PMDA「审查等手数料」官方页面逐项核验】
CE / FDA / NMPA acceleration	No formal mutual-recognition or reliance pathway exists with any single reference market, but FDA 510(k)/PMA data is broadly reused in PMDA technical review and is an explicit supporting factor for SAKIGAKE designation; CE MDR technical documentation is structurally reusable because both frameworks trace to IMDRF STED; an NMPA certificate carries essentially no formal weight in PMDA review — see Element 8

Market Overview

• Population: Approximately 124 million (2024); the highest elderly-population ratio in the world (approximately 30% aged 65+), sustaining strong structural demand for chronic-disease management, diagnostics, robotics/assistive devices, and elderly-care technology.
• Healthcare System: Universal health insurance (National Health Insurance plus Employees' Health/Social Insurance); public and private hospitals co-exist, and — critically — a medical device must obtain NHI reimbursement listing (保険収載) with an assigned point value before it can realize meaningful commercial volume; regulatory approval and reimbursement are two separate, sequential gates.
• Market Characteristics: The world's third- or fourth-largest medical device market by most industry estimates, with a market size on the order of JPY 3.5+ trillion. High receptivity to genuinely innovative technology, but real entry barriers — Japanese-language documentation, MAH/D-MAH structuring, and reimbursement negotiation must all be solved, not just the technical review. Domestic manufacturers (Olympus, Terumo, Fujifilm, Sysmex, Nipro, Shimadzu, Canon Medical, PHC) hold strong, technically sophisticated positions in endoscopy, cardiovascular devices, imaging, diagnostics, and dialysis; imported devices account for a substantial share of the market by value, particularly in advanced intervention, imaging, and implants.
• Regulatory Maturity: Extremely high. PMDA is globally recognized as one of the most technically rigorous device regulators, and Japan is one of the five founding regulatory authorities of the Medical Device Single Audit Program (MDSAP), alongside the US FDA, Health Canada, Australia's TGA, and Brazil's ANVISA — PMDA has accepted MDSAP audit reports as QMS conformity evidence since 2016. The regulatory framework was substantially modernized by the 2014 PMD Act (replacing the former Pharmaceutical Affairs Law), and expedited pathways — SAKIGAKE priority designation, the Conditional Approval System for medical devices (legalized September 2020, most recently updated May 2026), and the DASH for SaMD program — have been progressively expanded to close the gap between device availability abroad and in Japan (the so-called "device lag").

Regulatory Authority and Legal Framework

• Competent Authorities:
  • PMDA (独立行政法人医薬品医療機器総合機構) — conducts technical/scientific review of Shonin applications, QMS conformity assessment (directly or via document review of MDSAP/RCB evidence), consultation services, and post-market safety signal management. PMDA is the operational executing body but does not itself issue the final Shonin approval.
  • MHLW (厚生労働省) — issues the final Shonin approval certificate (承認書) based on PMDA's technical review recommendation, sets Certification Standards for the Ninsho route, and holds overall statutory authority for the PMD Act.
  • Registered Certification Bodies (登録認証機関, RCBs) — third-party bodies registered with MHLW that review and issue Ninsho certifications for eligible Class II and select Class III products; recognized RCBs include TÜV SÜD Japan, TÜV Rheinland Japan, BSI Group Japan, SGS Japan, DEKRA, and the Japan Quality Assurance Organization (JQA), among others.
• Official Portals: https://www.pmda.go.jp (Japanese); https://www.pmda.go.jp/english/index.html (English).
• Key Regulations:
  • PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Act No. 84 of 2013, in force since November 2014) — the top-level statute governing pharmaceuticals, medical devices, in vitro diagnostics, quasi-drugs, cosmetics, and regenerative medical products.
  • QMS Ministerial Ordinance No. 169 (2004, most recently updated 2021) — Japan's Quality Management System standard for medical device manufacturers, closely aligned with ISO 13485:2016 but carrying Japan-specific requirements (local document retention, supplier-oversight documentation).
  • GVP Ordinance (MHLW Ordinance No. 135) — Good Vigilance Practice standard governing MAH/D-MAH post-market safety management, including the mandatory GVP Manager role.
  • General Principles of Safety and Performance for Medical Devices (2020) — Japan's counterpart to EU MDR Annex I essential requirements.
  • Product-category-specific Certification Standards (認証基準) and guidance documents, jointly issued by MHLW/PMDA and periodically revised.

Element 1 — Device Classification and Pathway Branching

Classification is the single decision that determines the legal form (Todokede/Ninsho/Shonin), who reviews the application, whether a Certification Standard route is available, and how long the process realistically takes. Japan's four-class scheme tracks the GHTF/IMDRF risk model directionally, but the operative branching point within Class II and III is not the class number alone — it is whether MHLW has published a Certification Standard (認証基準), a JIS-referenced technical standard, for that specific product category.

Class	Local Term	Risk Level	Authorization Form	Reviewer	Certification Standard Route Available?	EU/FDA Rough Equivalent	Practical Timeline
Class I	一般医療機器 (General Medical Device)	Lowest	Todokede (届出) — notification	Prefectural government (administrative filing, no substantive review)	Not applicable	EU Class I / FDA Class I	Under 1 month
Class II — lower risk	管理医療機器 (Controlled Medical Device)	Low-moderate	Ninsho (認証) if a Certification Standard exists for the product; otherwise Shonin (承認)	Ninsho: a Registered Certification Body (RCB). Shonin: PMDA technical review + MHLW approval	Yes, for the majority of established Class II product categories	EU Class IIa / FDA Class II	Ninsho: 4–12 months. Shonin without a Certification Standard: 12–20 months
Class II — higher risk / Class III with standard	管理医療機器 / 高度管理医療機器	Moderate	Ninsho (認証) where a Certification Standard exists (a defined subset of Class III categories); otherwise Shonin	Ninsho: RCB. Shonin: PMDA + MHLW	Yes, for the specific product categories on the certification-eligible list	EU Class IIb / FDA Class II	Ninsho: 4–12 months. Shonin: 15–24 months
Class III	高度管理医療機器 (Specially Controlled Medical Device)	High	Shonin (承認) — Ninsho available only for the specific categories with a published Certification Standard	PMDA technical review + MHLW final approval	Category-dependent; most Class III products default to Shonin	EU Class III / FDA Class II/III	15–24 months
Class IV	高度管理医療機器（特定） (Specifically Designated, Specially Controlled Medical Device)	Highest	Shonin (承認)	PMDA full technical review (including clinical-data review) + MHLW final approval	No	EU Class III / FDA PMA	24–36 months

Branching logic in practice: the presence of a Certification Standard — a published JIS-referenced technical standard for the specific JMDN (Japanese Medical Device Nomenclature) code — is what actually splits a Class II or III device between the faster, RCB-reviewed Ninsho track and the slower, PMDA/MHLW-reviewed Shonin track, not the class number by itself. PMDA's application-category system layers a second, orthogonal branching dimension on top of Class I–IV: applications are further sorted into New Medical Devices (clearly novel structure/use/performance), Improved Medical Devices (neither wholly new nor a straight equivalent), and Subsequent Medical Devices (substantially equivalent to an already-approved device, some with established approval standards) — under MHLW's 2008 Medical Device Review Acceleration Action Program, the official target review periods are 12 months for new devices (9 months under priority review), 9 months for improved devices with clinical data, 6 months for improved devices without clinical data, and 4 months for subsequent devices. A device that looks like a straightforward Class III product on the risk table can still land in the slowest "New Medical Device" review lane if it has no established comparable product in Japan — confirm both dimensions (risk class and application category) before committing to a timeline. IVDs are legally classified as pharmaceuticals (体外診断用医薬品) rather than medical devices under the PMD Act but use a parallel Class I–IV risk framework — see the IVD section below.

Element 2 — License-Holder Logic: MAH, D-MAH, and the Foreign Special Approval Alternative

This is the decision that shapes commercial and regulatory control in Japan more than any other choice, and — unlike most of Japan's regional peers — Japan actually offers two structurally different routes, not one mandatory local-holder model.

• Standard route: a Japan-based Marketing Authorization Holder (MAH, 製造販売業者) is mandatory. The MAH holds an MHLW-issued manufacturing-and-marketing business license (製造販売業許可), is named as the owner of the Shonin/Ninsho certificate, lists the foreign manufacturer as the "Manufacturing Site" (製造所) on the certificate, and can submit supplemental or transfer applications independently, without the foreign manufacturer's signature. This is structurally similar to Korea's KLH model or China's local-agent-of-record concept, except that Japan additionally permits an alternative.
• Alternative route: Foreign Special Approval with a Designated MAH (D-MAH), available only for Class II, III, and IV devices — not Class I. Under this scheme, the foreign manufacturer itself retains ownership of the approval/certificate (PMDA refers to this party informally as the Foreign Restrictive/Special Approval Holder), and appoints a Japan-based D-MAH to act as its in-country regulatory agent — filing applications and STED dossiers on the manufacturer's behalf (requiring the foreign manufacturer's own signature on submissions), managing the Foreign Manufacturer Registration, handling incoming inspection/release decisions, running post-market safety reporting and recalls, and liaising with PMDA/MHLW/RCBs. The D-MAH does not own the certificate and cannot act unilaterally the way a standard MAH can.
• Distributor-affiliated MAH — a variant of the standard route in which a commercial distributor itself holds the MAH license, bundling the regulatory holder role with the commercial relationship. This is often the fastest and cheapest way to get to market because it uses the distributor's existing license and infrastructure, but it creates the same structural lock-in risk seen in Korea's and Southeast Asia's distributor-held models.

Model	Who Holds the Certificate	Control Retained by Manufacturer	Speed to Market	Relative Cost	Key Trade-off
Own Japanese subsidiary as MAH	Manufacturer's own Japan-incorporated entity	Full — registration, product-line decisions, and renewal sit entirely with the manufacturer	Slowest to stand up (entity formation, MAH license acquisition, staffing before product filing can even begin)	Highest (entity setup, local staff, ongoing GVP/GQP overhead)	Best for a long-term, high-volume Japan strategy where certificate control justifies the setup cost
Designated MAH (D-MAH) under Foreign Special Approval	The foreign manufacturer itself — Class II/III/IV only	High — the manufacturer owns the approval outright and can replace the D-MAH without transferring the certificate	Moderate — no Japanese entity required, but D-MAH sourcing and QMS-agreement negotiation still take time	Moderate (D-MAH service fee, no distribution margin claim, no entity-formation cost)	The structurally cleanest option for a foreign manufacturer that wants to keep certificate ownership without incorporating in Japan — not available for Class I
Distributor-affiliated MAH	Distributor's Japan-incorporated entity	Low — the distributor owns both the registration and the commercial relationship	Fastest (uses the distributor's existing MAH license and import infrastructure)	Lowest upfront cost	If the distributor relationship ends, the certificate does not automatically transfer — changing MAH requires a partial-change approval application (承認事項一部変更), which is procedurally burdensome and can interrupt supply

• D-MAH switching mechanics vs. MAH switching mechanics — this is the single most consequential structural fact on this page. Because the foreign manufacturer itself owns the certificate under the D-MAH/Foreign Special Approval model, changing D-MAH is comparatively simple: it is an administrative agent change, not a certificate transfer, and does not require the cooperation or consent of a departing commercial partner. Changing a standard MAH, by contrast, requires a formal partial-change approval application (承認事項一部変更) — a process that is procedurally burdensome, takes real time, and depends on the outgoing MAH's cooperation to hand over the underlying technical file. Conflating "who imports/distributes the product" with "who holds the certificate" — by defaulting to a bundled distributor-MAH arrangement without weighing the D-MAH alternative — is the most common structuring mistake foreign manufacturers make entering Japan, and it is avoidable precisely because Japan (unlike Korea, China, or most of Southeast Asia) offers a route that does not require surrendering certificate ownership to a local party at all.
• MAH license tiers (製造販売業許可の種別) — the type of MAH license required scales with the highest-risk product the MAH intends to handle:

License Type	Japanese Term	Devices Covered
Type 1 (第一種)	第一種医療機器製造販売業許可	All classes, including Class III/IV Shonin products
Type 2 (第二種)	第二種医療機器製造販売業許可	Class II devices (Ninsho or Shonin)
Type 3 (第三種)	第三種医療機器製造販売業許可	Class I devices (Todokede) only

• MAH/D-MAH qualification requirements: the entity must hold the appropriate license tier, designate a Responsible Technical Expert (責任技術者) meeting professional-qualification criteria, and maintain a post-market safety management system compliant with the GVP Ordinance — including a named GVP Manager. A D-MAH must additionally maintain a documented QMS agreement with the foreign manufacturer defining incoming-inspection, release-decision, and quality-escalation responsibilities.

Element 3 — Certificate Validity and Review-Timeline Ranges

Stage	Official/Statutory Target	Practical Reference Range
Todokede (Class I notification)	Administrative filing, no substantive review	Under 1 month
Ninsho (Class II/III with Certification Standard)	RCB self-set target, commonly cited around 4 months	4–12 months including QMS-evidence review
Shonin — Subsequent Medical Device (substantially equivalent)	4 months	6–12 months
Shonin — Improved Medical Device, no clinical data	6 months	9–15 months
Shonin — Improved Medical Device, with clinical data	9 months	15–20 months
Shonin — New Medical Device, standard review	12 months	15–24 months
Shonin — New Medical Device, priority review (non-SAKIGAKE)	9 months	12–18 months
Shonin — New Medical Device, SAKIGAKE-designated	6 months (target, from the pre-SAKIGAKE 12-month baseline)	9–15 months
PMDA written query (照会事項) clock-stop	Not counted toward the statutory review clock	Each round typically adds 3–6 months
Overseas QMS on-site inspection (where triggered)	Scheduled roughly 6–12 months after application	Can extend total timeline by 12–18 months; largely avoidable for facilities with a current MDSAP audit report, which PMDA has accepted as QMS conformity evidence since 2016
Shonin approval / Ninsho certification validity, once granted	No fixed expiry	Subject to periodic QMS conformity re-confirmation, commonly cited on a ~3–5 year cycle; design/process/labeling changes must be reported or re-approved as they occur

Why the official target and the real-world figure diverge: MHLW's target review periods (from the 2008 Medical Device Review Acceleration Action Program) measure only the active PMDA/RCB review clock — they exclude dossier pre-screening, administrative acceptance, and, most significantly, every round of PMDA's written query (照会事項) process, which functions much like the EU's clock-stop mechanism and is routine for Class III/IV Shonin submissions. Complex products commonly see 2–3 query rounds, each adding 3–6 months; budget the practical range as the working baseline for internal planning, not the official target figure. 【待核验：MHLW 2008 年医疗器械审查加速行动计划的官方时限数值来自 PMDA 日文页面二手转译，建议以 PMDA 官方最新时限公告页面核验现行数值是否已更新】

Element 4 — MAH/D-MAH In-Country Obligations

Holding (or acting as agent for) a Shonin approval or Ninsho certification is not a one-time compliance event. The MAH — or the D-MAH, acting on the foreign manufacturer's behalf — carries continuing operational duties for as long as the product remains on the Japanese market:

Obligation	What It Covers	Practical Driver
QMS Ministerial Ordinance No. 169 conformity	ISO 13485-aligned QMS, with Japan-specific requirements for local document retention and supplier oversight	PMDA accepts current MDSAP audit reports as conformity evidence (accepted since 2016), which can substitute for a dedicated PMDA on-site inspection
GVP Ordinance (No. 135) compliance	Good Vigilance Practice — the MAH/D-MAH must maintain a post-market safety management system with a named GVP Manager	Directly determines the quality and speed of adverse-event and recall reporting
GQP (Good Quality Practice)	Quality assurance for the marketing/distribution side, distinct from manufacturing-side QMS	Covers incoming inspection, release decisions, and storage/distribution quality control
Foreign Manufacturer Registration (FMR) / accreditation	Every relevant overseas manufacturing site — Design Facility, Main Assembling Plant, Sterilizer (if applicable), and Domestic (Japan-side) Distribution Center — must be individually registered with PMDA before or alongside the product application	Missing or stale FMR entries are a common, avoidable cause of application rejection or delay
Adverse-event (vigilance) reporting	Death or serious injury, unexpected serious adverse events, and infection incidents must be reported to PMDA within defined statutory windows; Periodic Safety Update Reports (PSURs) follow a class-dependent cycle	Death/serious injury: within 15 days. Unexpected serious AE: within 30 days. Infection incidents: within 30 days. PSURs: annually or biennially depending on class
Recall execution	The MAH/D-MAH must notify PMDA/prefectural authorities immediately upon recall initiation; recalls are classified Level I/II/III by severity	Misclassifying recall severity is an independent compliance failure regardless of the underlying product issue
Periodic reporting and change management	Annual sales-volume and safety-information reporting to MHLW/prefectural authorities; design, raw-material, or manufacturing-process changes require a partial-change approval application (承認事項一部変更) rather than simple notification	Treating a substantive change as a minor filing (or vice versa) creates real compliance exposure and can jeopardize the underlying approval

Practically, neither the MAH nor a D-MAH is a mailbox function — the competence of the named Responsible Technical Expert and GVP Manager materially affects PMDA query-response quality and inspection outcomes, and a foreign manufacturer that treats the local-holder relationship as a low-stakes administrative formality is under-pricing the risk of a botched query response, a late adverse-event report, or a mishandled QMS conformity renewal.

Element 5 — Fee Model: One-Time vs. Recurring

Japan's fee structure mixes moderate-to-substantial government review fees (which scale sharply with device class and clinical-data scope) with recurring commercial costs that typically dominate the real project budget.

Fee Item	Reference Amount	One-Time / Recurring
PMDA/prefectural fee — Todokede (Class I)	Minimal, largely administrative	One-time, per submission
PMDA application/review fee — Shonin, Class II	Approx. JPY 1,000,000–2,000,000 (~USD 7,000–14,000)	One-time, per submission
PMDA application/review fee — Shonin, Class III	Approx. JPY 3,000,000–6,000,000 (~USD 20,000–40,000)	One-time, per submission
PMDA application/review fee — Shonin, Class IV	Toward the higher end of, and potentially exceeding, the Class III range, depending on clinical-data scope	One-time, per submission
RCB (Ninsho) certification fee, Class II	Self-set by each RCB; commonly cited from approx. JPY 500,000 upward for straightforward certifications	One-time, per submission
PMDA formal consultation fee (pre-application, strategy, clinical)	Approx. JPY 1,000,000–3,000,000 per formal session (~USD 10,000+ for a 2-hour clinical/study consultation); a first ~30-minute introductory consultation is free	One-time, per consultation event; complex Shonin projects commonly use several
Japanese translation of the full technical dossier	USD 30,000–80,000, volume-dependent	One-time per submission (repeats on major revisions)
MAH / D-MAH service fee (annual retainer)	USD 15,000–80,000/year, depending on product complexity and scope of delegated responsibility	Recurring, annual
Registration consulting/agency fee (full service, Class III)	USD 50,000–150,000	One-time per project
QMS conformity assessment / overseas inspection-related costs	USD 20,000–50,000 (travel, preparation, and inspection logistics where an on-site PMDA visit is required rather than MDSAP-report reliance)	One-time to obtain, then a periodic re-confirmation cost
Japan-specific clinical trial (single center, where required)	USD 300,000–1,000,000+	One-time per submission cycle
Total estimate — Class III, clinical-data exemption	USD 150,000–350,000	—
Total estimate — Class III, including a Japan-specific clinical trial	USD 500,000–1,500,000+	—

【待核验：以上 PMDA 官方申请费具体数值为二手来源汇总（含 meddeviceguide.com 与原页面数据），本轮未能直接抓取 PMDA 官方「審査等手数料」费率页面逐项核验，建议以现行 PMDA 官方费率表为准】

Element 6 — Registration Forms: Todokede vs. Ninsho vs. Shonin

Japan's system has three legal forms, each with a materially different legal character and a different reviewing body:

Form	Japanese Term	Legal Character	Who Reviews	Applies To
Notification	届出 (Todokede)	Administrative filing; the prefectural government records the submission without a substantive safety/efficacy review before market entry	Prefectural government	Class I (一般医療機器) devices
Certification	認証 (Ninsho)	Substantive but expedited third-party review against a published Certification Standard (認証基準, a JIS-referenced technical standard) — conceptually similar to a European Notified Body's role	One of the Registered Certification Bodies (登録認証機関)	Class II devices, and the specific Class III categories with a published Certification Standard
Approval	承認 (Shonin)	Full substantive technical review by PMDA, followed by MHLW's final approval decision; the most rigorous of the three forms	PMDA (technical review) + MHLW (final approval)	Class II/III devices without a Certification Standard; all Class IV devices

Registered Certification Bodies (RCBs) commonly cited for Ninsho review:

RCB	Notes
TÜV SÜD Japan	International notified body also active in EU MDR/IVDR certification
TÜV Rheinland Japan	International notified body with parallel EU/US recognition
BSI Group Japan	Global standards and certification body
SGS Japan	Global testing, inspection, and certification body
DEKRA	International certification body
Japan Quality Assurance Organization (JQA)	Japan-domiciled certification body with long-standing Ninsho experience

A full, authoritative RCB list is maintained by MHLW/PMDA in Japanese only; confirm current RCB registration status and product-category scope directly before engagement.

Element 7 — Special Requirements

Japanese-Language Labeling and Package Insert (添付文書)

This is one of the two largest Japan-specific compliance workstreams on this page, alongside MAH/D-MAH structuring, and it must be planned from the start of dossier preparation, not translated at the end.

• Japanese is mandatory on every label and package insert. Per PMD Act Article 52 and related MHLW labeling rules, labels and the package insert (添付文書) must be built to Japan's own required content set — direct translation of a CE or FDA label is not, by itself, sufficient.
• Electronic package insert (eIFU) since August 2021: for professional-use (non-home-use) devices, the paper package insert was officially replaced by an electronic version registered with PMDA — every applicable IFU must be registered as an electronic file on the PMDA database and kept current; home-use devices not requiring a prescription remain outside this electronic-only requirement.

#	Mandatory Label/Package-Insert Element	Japanese Term
1	Device name	販売名
2	Intended use / effects and performance	使用目的又は効果
3	MAH or D-MAH name and address	製造販売業者の氏名及び住所
4	Manufacturer (manufacturing site) name and country	製造所の名称及び所在国
5	Approval/certification/notification number	承認番号 / 認証番号 / 届出番号
6	Lot number or manufacturing date	製造番号又は製造年月
7	Storage conditions and, where applicable, expiration date	保管方法及び有効期間
8	Warnings, contraindications, and precautions	警告・禁忌・使用上の注意
9	Single-use indicator, if applicable	再使用禁止の表示
10	Sterility status, if applicable	滅菌済みの表示
11	UDI (GS1-128 format)	UDI表示
12	Reference to the electronic package insert / registration	電子化された添付文書の参照

• UDI: Japan runs a UDI system referencing the IMDRF UDI Framework and using the GS1 standard; high-risk devices were brought into scope first (from 2023), with medium- and low-risk devices progressively following. UDI data must be registered in the MHLW/PMDA UDI database.
• Practical implication: budget a dedicated Japanese regulatory-labeling and package-insert pass distinct from the CE/FDA labeling package, and factor the 2021 electronic-IFU registration requirement into the submission timeline for professional-use devices.

PMDA Consultation System (相談制度)

The pre-submission consultation system is, by PMDA's own description, the single most effective tool for clarifying review expectations before formal filing — but scheduling constraints are a genuine, underappreciated source of timeline risk.

Consultation Type	Fee	Purpose
General Consultation	Free	Early-stage regulatory-pathway orientation; unlimited use
Pre-consultation meeting	Free	Clarifies discussion scope before a formal paid consultation
Regulatory Development Consultation	Free	Guidance on emerging regulatory frameworks (e.g., SaMD, novel technology categories)
RS Strategy Consultation	Fee-based	Testing/clinical-trial-requirement advice, candidate selection through proof-of-concept
Pre-application / Clinical Trial / Prior Assessment Consultation	Fee-based, commonly cited around JPY 1,000,000–3,000,000 (~USD 10,000+ for a 2-hour session)	Confirms review pathway, data requirements, and — for SAKIGAKE candidates — pre-application substantive review

• Scheduling lead time is a real planning constraint, not a formality: formal consultation slots have historically required 3–6 months lead time to secure, and PMDA's own published scheduling updates have at times shown consultation availability booked out many months in advance — confirm current slot availability directly with PMDA well before a target submission date, rather than assuming a consultation can be scheduled on short notice.
• Fees may change without notice, per PMDA's own guidance; the authoritative current fee schedule ("審査等手数料," Fees for Reviews and Face-to-Face Consultations) is published in Japanese only.

Local QMS Audit and MDSAP

• Japan's QMS Ministerial Ordinance No. 169 conformity assessment can be satisfied either by a dedicated PMDA/RCB on-site or document audit, or by submitting a current MDSAP audit report — Japan is one of the five founding MDSAP participating authorities (with the US FDA, Health Canada, Australia's TGA, and Brazil's ANVISA), and PMDA has accepted MDSAP reports as QMS conformity evidence since 2016. This is a genuine, well-established acceleration lever for manufacturers that already maintain MDSAP certification for the US/Canada/Australia/Brazil markets.
• Where MDSAP reliance is not available, PMDA/RCB on-site inspection scheduling can add 6–18 months to the overall timeline (see Element 3) — plan QMS-evidence strategy at the same time as the classification and pathway decision, not after submission.

Element 8 — Expedited and Shortcut Pathways: What Actually Compresses the Japan Timeline

This is the deepest section on this page, reflecting genuine search demand around Japan's expedited market-access system. Japan's expedited framework is a layered system, not a single fast lane — understanding which layer a product qualifies for (and which it does not) is the single highest-value planning exercise for any manufacturer targeting a faster Japan launch.

The four-tier review-speed ladder

Tier	Target Review Period	Eligibility	Legal Basis
Standard Shonin (New Medical Device)	12 months	Default — any new device without a faster designation	PMD Act, MHLW 2008 Review Acceleration Action Program
Priority Review (優先審査, non-SAKIGAKE)	9 months	Devices meeting defined priority criteria (e.g., addressing an unmet medical need) without full SAKIGAKE designation	PMD Act
SAKIGAKE Priority Designation	6 months (halved from the 12-month baseline)	Innovativeness, severity of the target disease, and prominent expected effectiveness, plus intent to file in Japan first or simultaneously among the first countries globally	Trial basis since FY2015; formally codified in the 2019 PMD Act revision
Conditional Approval System (条件付承認制度)	Not a fixed target — approval granted on limited clinical data with mandatory post-market conditions	Devices addressing diseases with serious impact on life, no existing effective treatment, and considerable difficulty in completing conventional clinical development	Administrative guidance from 2017; legally formalized September 1, 2020; regulatory updates effective May 1, 2026

SAKIGAKE Designation System (先駆け審査指定制度) in depth

• What it provides once designated: (a) Prioritized Consultation by PMDA, (b) pre-application substantive review, (c) Priority Review with a target timeframe of 6 months (versus the standard 12-month track), and (d) a dedicated Review Concierge assigned by PMDA to shepherd the application.
• Eligibility is deliberately narrow: the product must be genuinely innovative, address a disease with serious impact on life where existing treatment is inadequate, demonstrate prominent expected effectiveness (typically evidenced by Phase 1/2-equivalent clinical or strong nonclinical data), and — critically — its premarket application must be filed in Japan first, or simultaneously among the first countries globally. A device that has already been on the US or EU market for years with no Japan filing in progress will generally not qualify.
• Practical effect: SAKIGAKE is Japan's strongest formal acceleration lever, but it targets first-in-world or first-in-Japan innovation specifically — it is not a general-purpose fast lane for any device with FDA/CE approval.

Conditional Approval System for medical devices (条件付承認制度) in depth

• What it allows: approval based on limited clinical data where full conventional clinical development would be considerably difficult, in exchange for mandatory post-market conditions — ongoing quality/efficacy/safety investigation, formal risk-management measures, real-world data collection during commercial use, and defined appropriate-use safeguards.
• Who it targets: innovative medical devices addressing diseases with serious impact on life where no existing effective treatment exists — genuinely comparable in spirit to the EU MDR's exceptional-circumstances pathway or the FDA's Breakthrough Device-adjacent post-market data strategies, though administered under Japan's own distinct legal mechanism.
• Distinct from the regenerative-medicine-only conditional/time-limited approval scheme: Japan separately operates a conditional and time-limited approval pathway exclusively for regenerative medical products (cellular/gene therapies), governed by its own MHLW guidance (most recently updated March 2024) — do not conflate the two; the device-focused Conditional Approval System discussed here applies to medical devices, not regenerative products.

Foreign clinical data acceptance and ethnic sensitivity

• PMDA accepts foreign clinical data under the ICH E5 framework and increasingly leverages Multi-Regional Clinical Trials (MRCTs) designed under ICH E17 principles, particularly where the trial includes a sufficient Japanese/Asian patient subset.
• PMDA's posture has become measurably more flexible over time: a well-designed global MRCT with adequate Japanese/Asian representation can, in many cases, avoid the need for a standalone Japan bridging study.
• Ethnic sensitivity remains PMDA's independent, Japan-specific concern regardless of reference-market approval status. Even a device with FDA PMA and EU MDR CE already in hand may still be asked for supplementary Japanese-population data if the existing evidence package lacks an adequate East Asian patient subset — this is the most common scenario in which manufacturers are surprised that "FDA/CE approval didn't fully speed things up." Raising ethnic-sensitivity strategy at a Pre-submission consultation, before formal filing, is the standard way to avoid a mid-review data request that can add a year or more.

Quick Assessment: What FDA/CE/NMPA approval actually unlocks

Certificate	Acceleration Effect	Primary Mechanism
US FDA (510(k)/PMA)	⭐⭐⭐ Moderate-to-strong	FDA data (510(k) Summaries, PMA clinical data) is broadly reused in PMDA technical review; FDA approval or Breakthrough Device progress is an explicit supporting factor cited in SAKIGAKE eligibility discussions and materially eases MAH/D-MAH recruitment
EU CE (MDR/MDD/IVDR)	⭐⭐ Limited but real	CE MDR technical documentation (Annexes II/III, Clinical Evaluation Report, PMCF data) shares the IMDRF STED structure with PMDA's expected dossier, cutting document-reorganization effort; no formal expedited pathway is triggered by CE alone
China NMPA	⭐ Minimal	PMDA/MHLW do not recognize NMPA as a reference market; an NMPA certificate carries essentially no formal or informal weight in PMDA technical review

What FDA approval unlocks, specifically

• Clinical/technical evidence reuse: FDA 510(k) Summaries, De Novo Decision Summaries, and PMA clinical study data are accepted as supporting evidence in PMDA technical review, reducing (though not eliminating) the likelihood of additional Japan-specific data requests.
• SAKIGAKE eligibility signal: having obtained, or being close to obtaining, FDA approval or FDA Breakthrough Device designation is referenced by regulatory practitioners as a factor that strengthens a SAKIGAKE application, though it is not itself a codified eligibility criterion — the codified criteria remain innovativeness, disease severity, and prominent expected effectiveness with Japan-first filing intent.
• MAH/D-MAH recruitment leverage: Japanese MAH and D-MAH candidates commonly treat FDA approval history as a primary due-diligence input; products with FDA clearance in hand typically shorten MAH/D-MAH negotiation by a meaningful margin versus a product with no reference-market approval at all.

What CE approval unlocks, specifically

• Document-preparation efficiency: because EU MDR's technical file structure and PMDA's expected STED-based dossier both trace to the same IMDRF format, a CE technical file can be reorganized into a Japanese submission without a full rebuild, and literature/PMCF data cited in the CE Clinical Evaluation Report can be reused directly in the PMDA Clinical Evaluation (臨床評価) report's literature section.
• No formal timeline compression: unlike FDA data's role in SAKIGAKE discussions, CE approval alone does not trigger a formal PMDA fast lane — the benefit is real but confined to document-preparation efficiency and reviewer confidence, not a compressed statutory clock.
• Version matters: CE certificates issued under the legacy MDD (pre-2017) carry less practical weight in PMDA review than current EU MDR certificates.

What none of these certificates unlock

• No waiver of the MAH/D-MAH requirement, Japanese-language labeling, QMS Ordinance No. 169 conformity, or the periodic QMS re-confirmation cycle — every product needs a Japan-side regulatory holder and Japanese-compliant documentation regardless of reference-market approval.
• No classification mapping guarantee — an FDA Class II (510(k)) or EU Class IIa device does not automatically land in the equivalent Japanese class; MHLW/PMDA makes an independent classification determination against the JMDN system.
• No waiver of ethnic-sensitivity review — this is the single most common way a manufacturer's Japan timeline expectations, built around "we already have FDA/CE," turn out to be wrong; plan for the possibility of a Japan bridging data request from the outset.
• NMPA carries essentially no formal or informal weight — manufacturers holding both NMPA and FDA/CE approvals should lead with FDA/CE evidence in the Japan submission and not expect NMPA history to influence PMDA reviewers.

IVD-Specific Requirements

Aspect	Detail
Legal classification	IVDs are legally classified as pharmaceuticals (体外診断用医薬品, in vitro diagnostic pharmaceuticals) under the PMD Act, not as medical devices — but they use a parallel Class I–IV risk framework and a structurally similar Todokede/Ninsho/Shonin branching logic
Class I IVDs	Todokede (notification)
Class II IVDs with a Certification Standard	Ninsho via an RCB
Class II IVDs without a Certification Standard, and Class III/IV IVDs	Shonin — PMDA technical review + MHLW approval
Nomenclature	Governed by JMDN-equivalent codes announced in the MHLW Official Journal; once the applicable code is determined, the IVD's registration route and applicable Certification Standard, if any, follow largely automatically
MAH/D-MAH	The same MAH-or-D-MAH structural choice described in Element 2 applies to IVD marketing authorization holders
Companion diagnostics	Reviewed in close coordination with the paired therapeutic product's own PMDA review timeline; bridging and ethnic-sensitivity considerations from Element 8 apply with particular force to companion diagnostics validated primarily on non-Japanese populations

SaMD, AI, and Digital Health Medical Device Software Requirements

• DASH for SaMD (2020) and DASH for SaMD 2 (2023): MHLW launched "Digital Transformation Action Strategies in Healthcare for SaMD" on November 24, 2020, to build a review system that accounts for SaMD's distinct characteristics (rapid iteration, real-world performance data, algorithm updates) rather than applying hardware-device review logic unmodified. The second-generation strategy, DASH for SaMD 2, launched in 2023 and reorganized PMDA's dedicated SaMD office (established April 2021) into two specialized review teams by device category, expanding reviewer capacity and introducing a target 6-month review timeframe for SaMD products under priority review.
• Two-step approval for SaMD: PMDA/MHLW Notification No. 1116-2 establishes a "two-step approval" option specific to software's iterative development character — a first-step approval limited to the intended use/effects demonstrable from exploratory study results, followed by a second-step approval extending to the full intended use once clinical evidence from post-marketing clinical trials and/or real-world data has accumulated. This directly addresses the mismatch between SaMD's iterative development cycle and a conventional single-shot approval process.
• Qualification threshold: software embedded in a PC, mobile device, or general-purpose hardware is first assessed for whether it qualifies as a regulated medical device at all (i.e., whether malfunction could plausibly affect patient safety/health), with a centralized PMDA consultation desk available to confirm qualification status before a developer commits to a full regulatory strategy.
• Practical implication: foreign SaMD/DTx applicants should budget a Japan-specific software dossier and consultation pass distinct from a CE MDR or FDA 510(k)/De Novo software package, and should evaluate two-step approval eligibility early — it is one of the more genuinely novel accelerants available in Japan and is not widely mirrored elsewhere in Asia.

Registration Dossier Requirements

• Application Summary (申請概要): product overview, in Japanese.
• Technical documentation (CTD format or PMDA-specified format):
  • Product origin and development history
  • Performance/safety test data (electrical safety, EMC, biocompatibility, sterilization validation, referencing JIS/IEC/ISO standards)
  • Stability/shelf-life data
  • Risk-management file (JIS T 14971, Japan's ISO 14971 equivalent)
  • Clinical data — clinical trial report, or overseas clinical data plus literature review including an ethnic-sensitivity assessment
• QMS documentation: manufacturing-site information, quality manual (ISO 13485 or QMS Ordinance No. 169-conformant), manufacturing-process flow, and — where relied upon — a current MDSAP audit report.
• Labeling and package insert (添付文書): Japanese-language label specimen covering the mandatory elements in Element 7, and the electronic package insert registration for professional-use devices.
• Comparable-product analysis (for New/Improved category applications): a comparative table against an existing marketed product where one exists; for genuinely new technology, independent substantiation of safety and efficacy without reference to precedent.
• Foreign Manufacturer Registration evidence: confirmation that all relevant overseas sites (design, main assembly, sterilization, and Japan-side distribution) hold current PMDA registration.
• IVD-specific additions: JMDN-equivalent code confirmation and, for companion diagnostics, coordination documentation with the paired therapeutic's review.

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Adverse-event (vigilance) reporting (see also Element 4):
  • Death/serious injury: within 15 days of becoming aware
  • Unexpected serious adverse events: within 30 days
  • Infection incidents: within 30 days
  • Periodic Safety Update Reports (PSURs): annually or biennially depending on device class
  • Foreign manufacturers fulfill these obligations through the MAH or D-MAH, not directly.
• Recall rules: PMDA/prefectural authorities must be notified immediately upon recall initiation; recalls are classified Level I (life-threatening) / Level II (injury risk) / Level III (no direct hazard).
• Periodic reporting: annual sales-volume and safety-information reporting to MHLW/prefectural authorities; devices with high usage frequency may additionally require post-marketing surveillance (PMS) investigations.
• Change management: the MAH/D-MAH must classify each change correctly between simple notification and a partial-change approval application (承認事項一部変更) — misclassification either causes unnecessary delay or leaves a non-compliant change unfiled.

Import and Customs Requirements

• Import clearance: once approval/certification is granted, no additional import license is separately required; the importer must be the MAH/D-MAH itself or its authorized import agent.
• Customs requirements: the approval/certification/notification number must accompany the customs declaration; products under PMD Act control must be declared accordingly; medical radiation-emitting devices carry additional requirements.
• Labeling language: Japanese is mandatory on packaging at the point of market entry — see Element 7 for the full mandatory-content list.

Market Access Channels

Approval is the compliance entry point, not the commercial one — obtaining a Shonin approval or Ninsho certification does not equal being able to sell into hospitals and receive insurance reimbursement, and the two tracks should be planned in parallel, not sequentially.

• NHI reimbursement listing (診療報酬収載): a separate application to the Central Social Insurance Medical Council (中央社会保険医療協議会, Chuikyo) is required to obtain a reimbursement point value; this process typically takes 6–12 months, and considerably longer — sometimes exceeding 2 years — for genuinely innovative devices where pricing negotiation (including any innovation premium) is protracted. Devices without reimbursement listing can only be used in self-pay procedures, which severely limits realistic market volume — this is, by wide practitioner consensus, the single most commonly overlooked barrier for overseas companies entering Japan.
• Public hospital procurement: channeled through hospital pharmaceutical affairs committees (薬事委員会); Japan-based clinical evidence or a substantial body of usage cases is typically expected; university-affiliated and DPC (Diagnosis Procedure Combination) hospitals are key innovation-entry points.
• Private hospitals and specialist clinics: comparatively flexible, though still subject to reimbursement constraints; high-end self-pay clinics are a viable first entry point for premium imported devices ahead of a broader reimbursed-channel push.
• Trading companies and distributors: Japan's device distribution is highly dependent on specialized trading companies (商社); direct-sales models without a trading-company relationship are very difficult to execute independently at scale.

Main Players and Channel Map

Type	Representative Players	Market Meaning
Regulator / review	PMDA, MHLW, Registered Certification Bodies, prefectural governments	Determine classification, Todokede/Ninsho/Shonin routing, QMS conformity, Foreign Manufacturer Registration, labeling, and post-market surveillance
Payment / reimbursement	MHLW, Chuikyo, the NHI reimbursement system, DPC hospitals	Determine point values, innovation premiums, and realistic hospital-purchasing feasibility
Domestic medtech	Olympus, Terumo, Fujifilm, Sysmex, Nipro, Shimadzu, Canon Medical, PHC	Strong in endoscopy, cardiovascular devices, imaging, diagnostics, dialysis, consumables, and service networks
Multinational device companies	Medtronic, J&J MedTech, Abbott, Boston Scientific, GE HealthCare, Siemens Healthineers, Philips, BD, and similar players	Retain technical strength in advanced intervention, implants, imaging, and diagnostics, but need local MAH/D-MAH, reimbursement, and channel execution
MAH / D-MAH / trading and service	Registration-only MAH/D-MAH service firms, medical-device trading houses, specialist distributors, repair providers	Execute registration, import, QMS liaison, installation, training, receivables, and hospital relationships
End-use settings	University hospitals, cancer centers, DPC hospitals, specialty clinics, private hospitals, check-up/laboratory chains	Determine innovation reference use, reimbursed volume, and premium self-pay entry points

Market Entry Strategy and Key Risks

• Confirm both classification and application category early: a device's Class I–IV risk level determines Todokede/Ninsho/Shonin routing, but its independent classification as New/Improved/Subsequent Medical Device under PMDA's application-category system determines the applicable official review-timeline target — resolve both before committing to a launch date.
• Decide MAH vs. D-MAH deliberately, not by default: if certificate ownership matters strategically (and the product is Class II–IV, making D-MAH eligible), the Foreign Special Approval/D-MAH route is the structurally cleanest way to avoid the lock-in risk inherent in a distributor-affiliated standard MAH — this decision should be made before signing any distribution agreement, not after.
• Evaluate SAKIGAKE and Conditional Approval eligibility as early as product-development planning, not at filing: SAKIGAKE in particular requires Japan-first or Japan-simultaneous filing intent, which is a strategic decision, not a late-stage regulatory tactic.
• Plan reimbursement strategy in parallel with the approval application, not after: begin Chuikyo-facing reimbursement research at the time of Shonin/Ninsho application to avoid discovering the commercial-access barrier only after the certificate is already in hand.
• Key risks:
  • MAH lock-in risk: for products on the standard MAH route, choosing the wrong MAH is difficult and slow to reverse via partial-change approval — this is precisely the risk the D-MAH alternative is designed to avoid for eligible (Class II–IV) products.
  • Ethnic-sensitivity risk: even with FDA/CE approval in hand, PMDA may require Japan-specific bridging data, materially increasing time and cost — raise this at Pre-submission consultation, not mid-review.
  • Reimbursement-timeline risk: Chuikyo negotiation for innovative/high-value devices can run well beyond a year, decoupling "PMDA/MHLW-approved" from "commercially launched."
  • Query-driven delay risk: poor Japanese technical-document quality directly produces multiple PMDA query rounds, each adding 3–6 months — this is the most controllable of all Japan timeline risks.
  • Consultation-scheduling risk: formal PMDA consultation slots require meaningful lead time to secure; failing to book early is a self-inflicted delay.
• Practical tips:
  • Invest in professional, medical-device-experienced Japanese translation — PMDA reviewers are technically rigorous, and rough translation is a direct, avoidable cause of extra query rounds.
  • Where MDSAP certification already exists for other markets, lead with it in the QMS conformity strategy to avoid an unnecessary dedicated PMDA on-site inspection.
  • Use PMDA's free General Consultation and Pre-consultation meeting options early to scope the formal, paid consultation efficiently.
  • MEDTEC Japan and HOSPEQ remain leading venues for market research and identifying MAH/D-MAH and distributor candidates.

Frequently Asked Questions

Who regulates medical devices in Japan?

Regulation is split between two authorities working together: PMDA (Pharmaceuticals and Medical Devices Agency) conducts the technical/scientific review and QMS conformity assessment, while MHLW (Ministry of Health, Labour and Welfare) issues the final Shonin approval and sets the Certification Standards used for the Ninsho route. Registered Certification Bodies (RCBs) independently review and issue Ninsho certifications for eligible Class II/III devices without MHLW's direct involvement in that specific review.

What is the difference between MAH and D-MAH in Japan?

An MAH (Marketing Authorization Holder) is a Japan-based entity that owns the approval/certificate outright, files independently, and can be a manufacturer's own subsidiary or a distributor. A D-MAH (Designated MAH) is only available for Class II–IV devices under the Foreign Special Approval scheme: the foreign manufacturer itself retains ownership of the certificate, and the D-MAH acts purely as its in-country regulatory agent. Switching a D-MAH is comparatively simple because the certificate never left the manufacturer's hands; switching a standard MAH requires a formal partial-change approval application and can interrupt supply.

How does Japan's expedited/accelerated market-access system actually work?

It is a four-tier ladder, not a single fast lane: standard Shonin review targets 12 months; Priority Review (without full SAKIGAKE status) targets 9 months for qualifying devices; SAKIGAKE designation targets 6 months but requires genuine first-in-world/first-in-Japan innovation with prominent expected effectiveness; and the Conditional Approval System (legalized September 2020, updated May 2026) allows approval on limited clinical data with mandatory post-market risk-management conditions for devices addressing serious diseases lacking effective treatment. Most devices with existing FDA/CE approval qualify for none of these tiers automatically — eligibility must be assessed against each tier's specific criteria.

Does an existing FDA or CE approval speed up PMDA registration?

Partially, and the mechanism differs by certificate. FDA data (510(k) Summaries, PMA clinical data) is broadly reused in PMDA technical review and is a supporting factor cited in SAKIGAKE eligibility discussions and MAH/D-MAH recruitment, though it does not itself trigger a formal fast lane. CE MDR technical documentation is directly reusable as a drafting source because both frameworks trace to the IMDRF STED structure, cutting document-preparation time, but it likewise does not compress the statutory review clock on its own. Neither approval waives the MAH/D-MAH requirement, Japanese labeling, QMS Ordinance No. 169 conformity, or PMDA's independent ethnic-sensitivity review.

How long does Japan medical device registration actually take, end to end?

Realistic ranges by pathway: under 1 month for a Class I Todokede; 4–12 months for a Class II/III Ninsho certification; 15–24 months for a standard Class II/III Shonin approval; 24–36 months for a Class IV Shonin including new clinical-data review; and 9–15 months for a SAKIGAKE-designated device against its 6-month target. Each PMDA written-query round typically adds 3–6 months on top of these ranges, and reimbursement listing (6–12 months, longer for innovative devices) must be added before the device can actually generate hospital-channel revenue.

Is a Japanese entity mandatory to sell medical devices in Japan?

Not necessarily. The standard route requires a Japan-based MAH, which can be the manufacturer's own subsidiary or a distributor's entity. But for Class II–IV devices, the Foreign Special Approval/D-MAH route lets the foreign manufacturer retain the approval in its own name without incorporating in Japan, appointing a Japan-based D-MAH purely as a regulatory agent instead. Class I devices cannot use this alternative and must go through a standard Japan-based MAH under Todokede.

What is QMS Ministerial Ordinance No. 169, and does MDSAP help?

QMS Ministerial Ordinance No. 169 (2004, updated 2021) is Japan's Quality Management System standard, closely aligned with ISO 13485:2016 but carrying Japan-specific requirements around local document retention and supplier oversight. Yes — Japan is one of the five founding MDSAP participating authorities, and PMDA has accepted current MDSAP audit reports as QMS conformity evidence since 2016, which can avoid the need for a dedicated PMDA on-site inspection for manufacturers that already maintain MDSAP certification for other markets.

What is the SAKIGAKE Designation System, and who actually qualifies?

SAKIGAKE (先駆け審査指定制度) is Japan's top-tier expedited pathway, offering prioritized PMDA consultation, pre-application substantive review, a Review Concierge, and a 6-month priority review target (halved from the standard 12-month baseline). It was run on a trial basis from FY2015 and formally codified in the 2019 PMD Act revision. Eligibility is narrow: the product must be genuinely innovative, address a disease with serious life impact where existing treatment is inadequate, show prominent expected effectiveness, and — critically — be filed for premarket application in Japan first, or simultaneously among the first countries globally. A device already established for years in the US/EU market with no Japan filing underway typically does not qualify.

Official Sources and Verification Dates

• Pharmaceuticals and Medical Devices Agency — English portal: https://www.pmda.go.jp/english/index.html (fetched and confirmed 2026-08-17)
• PMDA — Regulations and Approval/Certification of Medical Devices (official, directly fetched): https://www.pmda.go.jp/english/review-services/reviews/0004.html (fetched and confirmed 2026-08-17; classification, Todokede/Ninsho/Shonin structure, and MAH requirement cross-checked here)
• PMDA — Software as a Medical Device (SaMD) (official, directly fetched): https://www.pmda.go.jp/english/review-services/reviews/0009.html (fetched and confirmed 2026-08-17; DASH for SaMD, two-step approval, SaMD office structure cross-checked here)
• PMDA — Strategy of SAKIGAKE by MHLW (official, directly fetched): https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html (fetched and confirmed 2026-08-17)
• PMDA — MDSAP audit report acceptance (official, directly fetched): https://www.pmda.go.jp/english/review-services/gmp-qms-gctp/0004.html (fetched and confirmed 2026-08-17; founding-authority status and 2016 acceptance date cross-checked here)
• PMDA — Consultation services overview (official, directly fetched): https://www.pmda.go.jp/english/review-services/consultations/0002.html (fetched and confirmed 2026-08-17)
• PMDA (Japanese) — Conditional Approval System for Medical Devices, etc. (official, directly fetched and translated): https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/devices/0042.html (fetched and confirmed 2026-08-17; September 2020 legalization and May 2026 update cross-checked here)
• PMDA (Japanese) — Ministerial Approval (Shonin) overview (official, directly fetched and translated): https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/devices/0035.html (fetched and confirmed 2026-08-17; New/Improved/Subsequent Medical Device review-timeline targets from the 2008 MHLW Review Acceleration Action Program cross-checked here)
• D-MAH system explainer (Japan-based regulatory consultancy) — secondary summary: https://www.jpnpro.com/dmah-summary-e.html (accessed 2026-08-17)
• MAH vs. DMAH, Foreign Special Approval System eligibility — secondary summary: https://credevo.com/articles/2022/12/05/marketing-authorization-holder-mah-designated-marketing-authorization-holder-dmah-for-product-registration-in-japan/ (accessed 2026-08-17)
• Japan medical device classification, JMDN structure — secondary summary: https://elendilabs.com/en/articles/jpn-medical-device-standards (accessed 2026-08-17)
• Japan medical device registration cost benchmarks — secondary summary: https://meddeviceguide.com/blog/medical-device-registration-cost-by-country-guide (accessed 2026-08-17)
• MDSAP and Japan device registration — secondary summary: https://www.freyrsolutions.com/blog/mdsap-and-device-registration-in-japan (accessed 2026-08-17)
• Foreign clinical data acceptance, ICH E5/E17, ethnic sensitivity in Japan — secondary summaries: https://intuitionlabs.ai/articles/pmda-regulatory-pathways-japan, PMC review of Asia-inclusive drug development (accessed 2026-08-17)
• IVD legal classification as pharmaceutical under PMD Act — secondary summary: https://www.emergobyul.com/services/registration-vitro-diagnostics-ivds-japan (accessed 2026-08-17)
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• Exact current PMDA official application/review fee schedule ("審査等手数料") by class and application category — the JPY/USD figures in the Quick Reference and Element 5 are compiled from secondary regulatory-services sources plus figures carried over from the prior version of this page; the official PMDA fee page was not directly and completely fetched during this verification pass.
• Whether the official MHLW 2008 Medical Device Review Acceleration Action Program target periods (New/Improved/Subsequent Medical Device) cited in Elements 1, 3, and 8 remain the current official targets, or have since been revised — sourced via a secondary-translated PMDA Japanese-language page rather than a current English-language primary confirmation.
• The precise legal article number and official English name of the "Foreign Special Approval" scheme within the PMD Act — described here via consistent secondary-consultancy sourcing (jpnpro.com, credevo.com), but no PMD Act article citation was independently confirmed during this pass.
• Whether the QMS conformity re-confirmation cycle is uniformly ~3–5 years across all device classes, or varies by class/product category — secondary sources give a general range without class-specific breakdown.